Q3 2020 Sales Performance

HIV: revenue breakdown 2019 Revenues of £4.9bn (+1% CER) gsk Products Regions Tivicay (-1%) Other £1.7bn Dovato (-) Juluca (>100%) £0.4bn (7%) (34%) US (-1%) £3.0bn (62%) £1.2bn (24%) Europe (-2%) Triumeq (+9%) £2.5bn (52%) Source: GSK Full year 2019 results release - February 2020 All growths at constant exchange rates (CER). Breakdown percentages are approximate £0.7bn (14%) International (+13%) 26

View entire presentation